Chemotherapy for patients with acute myeloid leukemia in first remission

Bradstock, Kenneth F.

doi:10.1007/s11899-006-0021-8

Cited by 4 publications

(3 citation statements)

References 28 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although remarkable remissions can be initially attained through chemotherapy in most AML patients, complete disease elimination remains rare. Promising approaches have been proposed, such as chimeric antigen receptor (CAR) T-cell therapy targeting CD33 combined with allogeneic hematopoietic cell transplantation [8, 9]. However, 75% of patients are still at risk of disease relapse and succumb to the disease within 5 years from diagnosis [10].…”

Section: Introductionmentioning

confidence: 99%

Identification of prognostic genes in the acute myeloid leukemia microenvironment

Huang

Zhang

Fan

et al. 2019

Aging

View full text Add to dashboard Cite

The tumor microenvironment (TME) has a strong influence on the progression, therapeutic response, and clinical outcome of acute myeloid leukemia (AML), one of the most common hematopoietic malignancies in adults. In this study, we identified TME-related genes associated with AML prognosis. Gene expression profiles from AML patients were downloaded from TCGA database, and immune and stromal scores were calculated using the ESTIMATE algorithm. Immune scores were correlated with clinical features such as FAB subtypes and patient’s age. After categorizing AML cases into high and low score groups, an association between several differentially expressed genes (DEGs) and overall survival was identified. Functional enrichment analysis of the DEGs showed that they were primarily enriched in the immune response, inflammatory response, and cytokine activity, and were involved in signaling processes related to hematopoietic cell lineage, B cell receptor, and chemokine pathways. Two significant modules, dominated respectively by CCR5 and ITGAM nodes, were identified from the PPI network, and 20 hub genes were extracted. A total of 112 DEGs correlated with poor overall survival of AML patients, and 11 of those genes were validated in a separate TARGET-AML cohort. By identifying TME-associated genes, our findings may lead to improved prognoses and therapies for AML.

show abstract

Section: Introductionmentioning

confidence: 99%

Identification of prognostic genes in the acute myeloid leukemia microenvironment

Huang

Zhang

Fan

et al. 2019

Aging

View full text Add to dashboard Cite

show abstract

“…The majority of patients with acute myeloid leukemia (AML) treated with intensive induction chemotherapy obtain a complete remission (CR) . However, despite consolidation chemotherapy and advances in stem cell transplantation (SCT), most of these patients eventually relapse and ultimately die from their disease .…”

Section: Introductionmentioning

confidence: 99%

Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy

et al. 2016

View full text Add to dashboard Cite

In patients with acute myeloid leukemia (AML), rapid reduction of circulating blasts with induction chemotherapy may serve as an in vivo marker of chemosensitivity. We performed a retrospective analysis of 363 patients with untreated AML who received induction chemotherapy in order to determine the relationship between day of blast disappearance (DOBD) and complete remission (CR) rates, event-free survival (EFS), and overall survival (OS). DOBD ≤5 vs. >5 was identified as the most discriminating cutoff for OS. DOBD >5 was observed in 35 patients (9.6%). The CR rate for patients with DOBD ≤5 vs. >5 was 74.0% and 28.6%, median EFS was 9.4 months and 1.8 months, and median OS was 17.1 months and 5.8 months, respectively (P<0.001 for all). DOBD >5 was independently associated with a lower CR rate and shorter EFS and OS (P<0.001 for all). DOBD >5 retained prognostic significance for EFS and OS when patients were stratified by cytogenetic risk group, de novo vs. secondary or therapy-related AML, European LeukemiaNet-based risk groups, and whether CR was achieved. We propose DOBD >5 as a simple and early marker of disease resistance that identifies patients with poor prognosis who otherwise may not be identified with existing risk stratification systems.

show abstract

“…Bradstock 2006), have shown promise, 75% of patients still face the risk of relapse and death within ve years of diagnosis. Therefore, the identi cation of potential biomarkers is crucial for the diagnosis, treatment, and prognosis of pediatric AML patients.The Wnt signaling pathway holds signi cant importance in embryonic and organ development, serving as a crucial regulator of various cellular processes such as proliferation, differentiation, polarization, migration, and apoptosis(Sturgeon et al 2014;Logan and Nusse 2004;Niehrs 2012).…”

mentioning

confidence: 99%

WNT6 affects the prognosis of pediatric acute myeloid leukemia through regulation of Wnt signaling pathway activity

Zhang,

Lu,

et al. 2023

Preprint

View full text Add to dashboard Cite

Purpose Pediatric acute myeloid leukemia (AML) is associated with a dismal prognosis, underscoring the urgent need to identify potential biomarkers that can aid in the management of pediatric AML patients. Methods The adult AML dataset GSE201492 was partitioned into distinct prognostic groups following the identification of key genes through the screening of differentially expressed genes, enrichment analysis, and protein-protein interaction (PPI) analysis. Subsequently, these key genes were validated in the pediatric AML dataset obtained from the TARGET database, as well as in the data of pediatric AML patients diagnosed at the First Affiliated Hospital of Zhengzhou University. Finally, the association between WNT6 and the Wnt signaling pathway was investigated using the AML drug resistance dataset (GSE214158) and the WNT6 knockout dataset (GSE160039). Results Through the analysis of different prognostic groups in adult AML, researchers identified five key genes. The results from the TARGET database and clinical samples showed that pediatric AML patients with low expression of the gene WNT6 had better overall survival. In a dataset where WNT6 was knocked down, there was a significant decrease in the Wnt signaling pathway score. In another dataset about AML resistance, there was a statistically significant difference in Wnt signaling pathway scores, with the UTX knockout group having lower scores. Conclusion The upregulation of WNT6 has been recognized as a predictive factor for adverse prognoses in pediatric AML. Additionally, it contributes to the emergence of drug resistance in AML by modulating the functionality of the Wnt signaling pathway.

show abstract

Chemotherapy for patients with acute myeloid leukemia in first remission

Cited by 4 publications

References 28 publications

Identification of prognostic genes in the acute myeloid leukemia microenvironment

Identification of prognostic genes in the acute myeloid leukemia microenvironment

Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy

WNT6 affects the prognosis of pediatric acute myeloid leukemia through regulation of Wnt signaling pathway activity

Contact Info

Product

Resources

About